Document is current
Any future updates will be listed below
-
Authors
Lemanska, Agnieszka http://orcid.org/0000-0003-4849-2430
Byford, Rachel C.
Cruickshank, Clare
Dearnaley, David P.
Ferreira, Filipa
Griffin, Clare
Hall, Emma
Hinton, William
de Lusignan, Simon
Sherlock, Julian
Faithfull, Sara
-
Funding
Funding for this research was provided by:
University of Surrey (FHMS)
- License Information
-
More Information
Article History
Received: 26 February 2020
Accepted: 8 July 2020
First Online: 25 July 2020
Ethics approval and consent to participate
: A National Health Service ethics approval was obtained from the West of Scotland Research Ethics Committee 1 (approval number 16/WS/0076). Royal College of General Practitioners Research and Surveillance Centre has approved the study protocol and granted permission to conduct the study (data request number: RSC_0315). The trial dataset was shared under a data sharing agreement between the Institute of Cancer Research and the University of Surrey in accordance with the Institute of Cancer Research Clinical Trials and Statistics Unit’s data sharing policy. All patient personally identifiable data in the Royal College of General Practitioners Research and Surveillance Centre dataset are pseudonymised (de-identified) at the point of extraction from practices and before data are transferred to the University of Surrey.
: Not applicable.
: DD has received honoraria for advisory boards with Janssen Pharma. Abiraterone acetate was developed at the Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. DD is on the Institute’s Rewards to Inventors list for abiraterone acetate. DD holds patent EP1933709B1 for a Location and Stabilisation Device. EH declares research funding to Institute of Cancer Research from Accuray and Varian. All other authors declare that they have no competing interests.
